Agios Pharmaceuticals Discontinues Blood Cancer Drug Tebapivat After Phase 2 Trial Failure
Key Insights
Agios Pharmaceuticals terminated development of tebapivat for lower-risk myelodysplastic syndromes (search) after a 65-patient mid-stage trial failed to meet predefined efficacy thresholds.
The pyruvate kinase (search) activator was tested in three once-daily oral doses over 24 weeks, with the primary endpoint being transfusion independence for at least eight weeks.
Despite the setback in blood cancer (search), Agios will continue evaluating tebapivat for sickle cell disease (search) with early results anticipated in the second half of 2026.
Agios Pharmaceuticals announced Friday it will discontinue development of its experimental drug tebapivat for treating lower-risk myelodysplastic syndromes (search) (LR-MDS) after a mid-stage clinical trial failed to demonstrate sufficient therapeutic benefit. The Cambridge, Massachusetts-based rare disease-focused drugmaker's shares fell 1.7% in morning trading following the announcement.
Trial Design and Results
The 65-patient study evaluated three once-daily oral doses of tebapivat administered over 24 weeks in patients with LR-MDS and anemia (search), many of whom had previously received other treatments. The primary endpoint focused on achieving transfusion independence for at least eight weeks in this patient population.
Myelodysplastic syndromes (search) represent a group of cancers where bone marrow fails to produce adequate healthy blood cells, with some cases potentially progressing to leukemia (search). The trial specifically targeted the lower-risk subset of these conditions.
According to the company, the study did not meet the predefined threshold necessary to advance tebapivat's development for this indication. However, the drug demonstrated a favorable safety profile with no new safety concerns identified during the trial period.
Mechanism of Action
Tebapivat belongs to a class of therapeutics known as pyruvate kinase (search) (PK) activators. These compounds work by enhancing an enzyme within red blood cells, enabling them to function more effectively. This mechanism represents a novel approach to addressing the underlying cellular dysfunction characteristic of certain blood disorders.
Analyst Perspective
J.P. Morgan analyst Tessa Romero characterized the negative outcome as unsurprising, citing the trial's inherent risks from the outset. She pointed to the variability of myelodysplastic syndromes (search) and the heavily pre-treated nature of the patient population as contributing factors to the study's challenges.
Continued Development in Sickle Cell Disease
Despite the setback in blood cancer (search) applications, Agios will maintain its development program for tebapivat in sickle cell disease (search). The company expects to report early results from this indication in the second half of 2026, providing another potential pathway for the pyruvate kinase (search) activator.
Portfolio Implications
The discontinuation occurs as Agios continues the commercial rollout of Aqvesme (search), its approved treatment for certain inherited blood disorders. According to Romero, Aqvesme may also hold potential for treating sickle cell disease (search), providing the company with multiple approaches to address this patient population.
The decision to halt the LR-MDS program reflects the challenging nature of drug development in rare hematologic malignancies, where patient heterogeneity and limited treatment history can complicate clinical trial design and interpretation.